Compare BWEN & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWEN | VRCA |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.8M | 107.5M |
| IPO Year | 2009 | 2018 |
| Metric | BWEN | VRCA |
|---|---|---|
| Price | $3.98 | $5.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 388.8K | 28.8K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 360.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $146,785,000.00 | $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.37 | $94.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $1.88 | $3.28 |
| 52 Week High | $5.52 | $9.82 |
| Indicator | BWEN | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 41.04 | 45.47 |
| Support Level | $3.75 | $5.32 |
| Resistance Level | $4.15 | $6.53 |
| Average True Range (ATR) | 0.51 | 0.39 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 6.02 | 32.21 |
Broadwind Inc is a precision manufacturer of structures, equipment, and components for clean technology and other specialized applications. The company provides technologically high-value products to customers with complex systems and stringent quality standards that operate in the energy, mining, and infrastructure sectors in the United States of America. Its capabilities include heavy fabrications, welding, metal rolling, coatings, gear cutting and shaping, gearbox manufacturing and repair, heat treatment, CNG decompression, precision machining, assembly, engineering, and packaging solutions, among others. The company operates in four reportable segments: Heavy Fabrications, which generates the maximum revenue, Gearing, Industrial Solutions, and Corporate.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.